Phase II/III trial of hyperimmune anti-COVID-19 intravenous immunoglobulin (C-IVIG) therapy in severe COVID-19 patients: study protocol for a randomized controlled trial

Overview of attention for article published in Trials, November 2022

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (74th percentile)

Mentioned by

policy: 1 policy source

twitter: 3 X users

Citations

dimensions_citation: 1 Dimensions

Readers on

mendeley: 14 Mendeley

Summary Policy documents X Dimensions citations

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 1,753 followers.

RT @DrFarahFarhan1: Another badge 🌟 https://t.co/xmKw2v7c8p https://t.co/dBjz0o5Gse

Reply Repost Favourite

Another badge 🌟 https://t.co/xmKw2v7c8p https://t.co/dBjz0o5Gse

Reply Repost Favourite

Phase II/III trial of hyperimmune anti-COVID-19 intravenous immunoglobulin (C-IVIG) therapy in severe COVID-19 patients: study protocol for a randomized controlled trial https://t.co/DST54fO4Rf

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.